In this article, read about the prevalence of age-related macular degeneration and InMed’s promising preclinical studies of INM-089, a small molecule drug candidate in development as a potential treatment for age-related macular degeneration.
Excerpt:
Results from several in vitro and in vivo studies demonstrated several pharmacological effects in the potential treatment of dry AMD. These include:
- providing neuroprotection of photoreceptors and improving photoreceptor function
- preserving retinal function in the back of the eye
- improving integrity of the retinal pigment epithelium (“RPE”)
- improve the thickness of “outer nuclear layer” (“ONL”) of the retina where photoreceptors are located (Based on widely accepted ocular research, the thickness of the outer nuclear layer is strongly correlated with photoreceptor preservation and visual acuity.)
INM-089 is also a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). CB1 and CB2 receptors are both part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses.
Full article here.
